MX357770B - Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. - Google Patents
Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.Info
- Publication number
- MX357770B MX357770B MX2013002722A MX2013002722A MX357770B MX 357770 B MX357770 B MX 357770B MX 2013002722 A MX2013002722 A MX 2013002722A MX 2013002722 A MX2013002722 A MX 2013002722A MX 357770 B MX357770 B MX 357770B
- Authority
- MX
- Mexico
- Prior art keywords
- sdf
- disorder
- disease
- nucleic acids
- cancer treatment
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 10
- 201000010099 disease Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 abstract 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009397 | 2010-09-09 | ||
| PCT/EP2011/004554 WO2012031773A1 (en) | 2010-09-09 | 2011-09-09 | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013002722A MX2013002722A (es) | 2013-06-28 |
| MX357770B true MX357770B (es) | 2018-07-24 |
Family
ID=44653255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002722A MX357770B (es) | 2010-09-09 | 2011-09-09 | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20130310442A1 (enExample) |
| EP (1) | EP2613789B1 (enExample) |
| JP (1) | JP6243736B2 (enExample) |
| KR (1) | KR101937939B1 (enExample) |
| CN (1) | CN103108641B (enExample) |
| AU (1) | AU2011300818B2 (enExample) |
| BR (1) | BR112013005664B8 (enExample) |
| CA (1) | CA2810950C (enExample) |
| DK (1) | DK2613789T3 (enExample) |
| ES (1) | ES2678497T3 (enExample) |
| MX (1) | MX357770B (enExample) |
| RU (1) | RU2679495C2 (enExample) |
| SG (2) | SG10201506725QA (enExample) |
| WO (1) | WO2012031773A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103108641B (zh) * | 2010-09-09 | 2016-01-13 | 诺松制药股份公司 | Sdf-1结合性核酸及其在癌症治疗中的用途 |
| EP3443095A1 (en) * | 2016-04-15 | 2019-02-20 | Noxxon Pharma AG | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors |
| JP7327855B2 (ja) | 2020-06-26 | 2023-08-16 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| WO1999048528A1 (en) | 1998-03-24 | 1999-09-30 | Chugai Seiyaku Kabushiki Kaisha | Vascularization inhibitors |
| EP2308996A1 (en) * | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| CN1250711C (zh) * | 2000-06-26 | 2006-04-12 | 威尔斯达特生物制剂公司 | 用病毒清除细胞 |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20060019917A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
| DK1417488T3 (da) | 2001-06-07 | 2007-03-05 | Chemocentryx Inc | Cellemigrasionsassay |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| DK2431377T3 (en) | 2001-10-26 | 2017-08-14 | Noxxon Pharma Ag | Modified L-nucleic acids |
| ATE441706T1 (de) | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| JP2006524242A (ja) * | 2003-03-27 | 2006-10-26 | エモリー ユニバーシティー | Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 |
| MXPA05011022A (es) | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| WO2005099768A2 (en) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| CA2585664C (en) | 2004-11-05 | 2014-05-20 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| WO2006126209A1 (en) * | 2005-05-26 | 2006-11-30 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| CA2619828A1 (en) * | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
| EP2041282B1 (en) | 2006-07-18 | 2018-01-03 | Noxxon Pharma AG | Sdf-i binding nucleic acids |
| EP2046834B9 (en) * | 2006-08-11 | 2013-04-10 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| EP2097451A2 (en) * | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
| CN101796188B (zh) | 2007-08-06 | 2014-10-29 | 诺松制药股份公司 | Sdf-1结合核酸及其用途 |
| CN103108641B (zh) * | 2010-09-09 | 2016-01-13 | 诺松制药股份公司 | Sdf-1结合性核酸及其在癌症治疗中的用途 |
-
2011
- 2011-09-09 CN CN201180043233.4A patent/CN103108641B/zh active Active
- 2011-09-09 EP EP11757776.7A patent/EP2613789B1/en active Active
- 2011-09-09 RU RU2013115739A patent/RU2679495C2/ru active
- 2011-09-09 JP JP2013527497A patent/JP6243736B2/ja active Active
- 2011-09-09 SG SG10201506725QA patent/SG10201506725QA/en unknown
- 2011-09-09 US US13/821,669 patent/US20130310442A1/en not_active Abandoned
- 2011-09-09 DK DK11757776.7T patent/DK2613789T3/en active
- 2011-09-09 SG SG2013011150A patent/SG188220A1/en unknown
- 2011-09-09 BR BR112013005664A patent/BR112013005664B8/pt active IP Right Grant
- 2011-09-09 KR KR1020137006584A patent/KR101937939B1/ko active Active
- 2011-09-09 ES ES11757776.7T patent/ES2678497T3/es active Active
- 2011-09-09 AU AU2011300818A patent/AU2011300818B2/en active Active
- 2011-09-09 MX MX2013002722A patent/MX357770B/es active IP Right Grant
- 2011-09-09 WO PCT/EP2011/004554 patent/WO2012031773A1/en not_active Ceased
- 2011-09-09 CA CA2810950A patent/CA2810950C/en active Active
-
2015
- 2015-11-20 US US14/947,173 patent/US9387221B2/en active Active
-
2016
- 2016-07-03 US US15/201,477 patent/US10093934B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG188220A1 (en) | 2013-04-30 |
| SG10201506725QA (en) | 2015-10-29 |
| BR112013005664B8 (pt) | 2023-04-25 |
| CA2810950A1 (en) | 2012-03-15 |
| EP2613789B1 (en) | 2018-04-18 |
| KR20130114094A (ko) | 2013-10-16 |
| WO2012031773A1 (en) | 2012-03-15 |
| US20160355821A1 (en) | 2016-12-08 |
| MX2013002722A (es) | 2013-06-28 |
| DK2613789T3 (en) | 2018-07-23 |
| BR112013005664A2 (pt) | 2020-08-04 |
| RU2679495C2 (ru) | 2019-02-11 |
| ES2678497T3 (es) | 2018-08-13 |
| EP2613789A1 (en) | 2013-07-17 |
| US9387221B2 (en) | 2016-07-12 |
| CN103108641A (zh) | 2013-05-15 |
| AU2011300818A1 (en) | 2013-03-07 |
| AU2011300818B2 (en) | 2015-11-12 |
| CA2810950C (en) | 2023-02-14 |
| KR101937939B1 (ko) | 2019-01-11 |
| JP6243736B2 (ja) | 2017-12-06 |
| US10093934B2 (en) | 2018-10-09 |
| US20160095875A1 (en) | 2016-04-07 |
| JP2013540725A (ja) | 2013-11-07 |
| HK1184699A1 (zh) | 2014-01-30 |
| RU2013115739A (ru) | 2014-10-20 |
| US20130310442A1 (en) | 2013-11-21 |
| BR112013005664B1 (pt) | 2021-11-03 |
| CN103108641B (zh) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| PH12015500832A1 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
| IN2015DN00450A (enExample) | ||
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| WO2012038504A3 (en) | Breast cancer therapeutics | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| WO2014111458A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
| BR112013029182A2 (pt) | método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas | |
| EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| IN2012DN02195A (enExample) | ||
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| WO2010108657A3 (en) | C5a binding nucleic acids and the use thereof | |
| WO2012119989A3 (en) | Antibodies against cadmi for the diagnosis and treatment of cancer | |
| GB201004761D0 (en) | Method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |